Compositions and methods for the induction of CD8+ T-cells

Patent metadata

Field	Value
Publication number	US-10695412-B2
Application number	US-201916421578-A
Country	US
Kind code	B2
Filing date	May 24, 2019
Priority date	Dec 23, 2016
Publication date	Jun 30, 2020
Grant date	Jun 30, 2020

Abstract

Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

First claim

The invention claimed is:

1. A method for treating cancer in a subject undergoing cancer immunotherapy, the method comprising administering to the subject a pharmaceutical composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 99% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, in a therapeutically effective amount to treat the cancer, wherein the pharmaceutical composition is formulated for delivery to the intestine of the subject.

2. The method of claim 1 , wherein said cancer immunotherapy comprises administering an anti-cancer agent to the subject.

3. The method of claim 2 , wherein the anti-cancer agent is an immune checkpoint inhibitor.

4. The method of claim 3 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor.

5. The method of claim 3 , wherein the immune checkpoint inhibitor is nivolumab.

6. The method of claim 3 , wherein the immune checkpoint inhibitor is pembrolizumab.

7. The method of claim 3 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.

8. The method of claim 1 , further comprising administering an antibiotic prior to administering the pharmaceutical composition or administering multiple doses of an antibiotic prior to administering the pharmaceutical composition.

9. The method of claim 8 , wherein the antibiotic is kanamycin, gentamicin, colistin, metronidazole, vancomycin, clindamycin, fidaxomicin or cefoperazone.

10. The method of claim 9 , wherein the antibiotic is vancomycin.

11. The method of claim 1 , wherein the cancer is a carcinoma or an adenocarcinoma.

12. The method of claim 1 , wherein the cancer is melanoma, head and neck cancer, stomach cancer, esophageal cancer, non-small cell lung cancer or colorectal cancer.

13. The method of claim 12 , wherein the cancer is head and neck cancer.

14. The method of claim 12 , wherein the cancer is stomach cancer.

15. The method of claim 12 , wherein the cancer is esophageal cancer.

16. The method of claim 12 , wherein the cancer is non-small cell lung cancer.

17. The method of claim 12 , wherein the cancer is colorectal cancer.

18. The method of claim 5 , further comprising administering an antibiotic prior to administering the pharmaceutical composition.

19. The method of claim 18 , wherein the antibiotic is vancomycin.

20. The method of claim 12 , wherein the cancer is melanoma.

Assignees

• Univ Keio
• Univ Tokyo

Inventors

• Honda Kenya
• Tanoue Takeshi
• Hattori Masahira
• Kawakami Yutaka

Classifications

• C12Q1/689 Primary

  for bacteria · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/116

  Polyvalent bacterial antigens · CPC title

• C12N1/20 Primary

  Bacteria; Culture media therefor · CPC title

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title